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Abstract
Cancer is the second leading cause of death in the United States. This
year, an estimated 577,190 Americans will die as a result of this family of
diseases. Finding cancer at its most treatable stage gives patients the greatest
chance of recovery; novel imaging agents that target primary and metastasized
tumors offer hope for improved prognoses in the future. Based on the hypothesis
that vitamin B12 (B12) and its association with specific transport proteins could
offer selective access to cancer cell lines, a series of B12-based imaging agents
were synthesized, characterized, and assayed for both in vitro and in vivo
functions. A water soluble B12-Re(I) probe that incorporated the thiazole linkerchelator moiety was used to demonstrate the presence of cubilin in A549 lung
cancer cells, and a B12-64Cu probe was shown to selectively target tumor cells
through specific receptors for B12 in a mouse model. These findings suggest that
B12-based bioprobes have great promise for cancer cell lines in vitro and targeting
tumors as imaging agents in vivo. The remarkable B12 bioprobes developed here
have a future as tools to better understand the biochemistry of B12 specifically and
the physiology of cancer more generally, a fascinating interface of two discrete
fields of study.

© Anna Kahkoska, April 24, 2013
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Preface

Diseases desperate grown
By desperate appliance are relieved,
Or not at all.

(From William Shakespeare's Hamlet, Act IV, Scene III)
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Project Overview

The overarching goal of this research was to synthesize imaging agents
that selectively target tumor cells through specific receptors for vitamin B12 (B12).
B12 is essential for cellular metabolism, growth, and division, and all living cells
require it for survival.1 Mammals cannot synthesize B12, so they must obtain it
through the diet. As a result, the human body has developed a complex dietary
uptake system based on soluble transport proteins in the mouth (haptocorrin, HC),
intestine (intrinsic factor, IF) and circulatory system (transcobalamin II, TCII).2

The construction of the B12-based probes presented in the future chapters
was based on the hypothesis that the B12 pathway can be exploited to offer a
tropism for cancer cells, due to the fact that certain cancer cell lines overexpress
uptake receptors for TCII (CD320 receptors) in order to meet the increased B12
demands of their rapid and uncontrolled growth. In addition, it was recently
discovered that some cell lines, like those of pancreatic cancer, express
membrane-bound HC de novo. This HC finding has great potential for an even
more specific targeting of cancer cells.

The specific aims were to synthesize, characterize, and assay a series of
B12-based imaging agents for both in vitro and in vivo functions, including a
fluorescent B12-based probe with which to screen cell lines for receptor targets
and a radiolabeled B12-based probe with which to target tumors in living
organisms.

2
2

Cancer

2.1 Pathology
Cancer, or malignant neoplasm, describes not just one disease, but a host
of diseases marked by unrestrained proliferation of abnormal cells.3 Unlike
regular cells, which undergo scheduled differentiation and apoptosis, cancer cells
divide uncontrollably, invade normal tissues, and may metastasize to other tissues
and organs.3 The mechanisms by which cells become cancerous are genetic and
environmental; cancer is thought to occur by DNA mutations which inhibit
normal cell signaling and apoptosis. Cancer can occur in nearly every tissue in the
body, and different types of cancers are clinically treated as distinct diseases; each
is associated with unique risk factors, prognoses, and treatments.4 Prostate
cancer, breast cancer, lung cancer, colorectal cancer, and melanoma are prevalent
in the US today.5

While the epidemiology of cancer is complex to study, it has been shown
that viral infections such as infection by human papilloma virus6, environmental
factors such as UV radiation from the sun,7and lifestyle factors such as smoking
tobacco8 are associated with the development of cervical cancer, skin cancer, and
lung cancer, respectively. In order to resolve the genetic mechanisms of cancer,
scientists are focused on sequencing the cancer genome to identify particularly
high-risk mutations that contribute to cancer development and recurrence.9
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2.2 Epidemiology
The American Cancer Society estimates that 577,190 Americans are
expected to die as a result of cancer in 2013.4 In 2012, cancer was cited as the
second leading cause of death in the US.5 Based on rates from 2007-2009,
41.24% of men and women born today will be diagnosed with a form of cancer at
some point during their lifetime.5

However, trends in epidemiology reflect advances in the field that allow
physicians to diagnose and treat cancer more effectively; over the past three
decades, the 5-year survival rate patients diagnosed with cancer has improved
from 49% to 67%.4 The NCI emphasizes that finding cancer at its most treatable
stage gives patients the greatest chance, yet, there is still a great need for
enhanced methods of detection, early or otherwise.4 Currently, tumors are most
often detected via blood-work, X-rays, computed tomography scans, magnetic
resonance imaging scans, and positron emission tomography scans.10

Finding novel imaging agents that selectively highlight primary and
metastasized tumors could radically improve cancer survival rates by permitting
better diagnoses and earlier intervention. This capstone project identifies new and
important imaging techniques using B12.
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2.3 Metastasis
Metastasis refers to the spread of cancer from the site of a malignant
tumor in one part of the body to other organs or tissues.11 Commonly, a piece of
the original tumor, termed the primary tumor, breaks away and enters the
bloodstream or lymphatic system, which circulates these cells to a different part
of the body via hematogeneous or lymphatic spread, respectfully.12 These cells
can form a tumor in a new site, termed the metastatic tumor. Because the
metastatic tumor is composed of cells from the primary tumor, it retains markers
or antigens on the cell surface that can be used to indicate the primary site of the
cancer.13 There are certain patterns of metastasis that are well-characterized
(Table 2.1).12 The most common sites of metastasis from solid tumors are the
lungs, bones, liver, and brain.13
Cancer type
Breast
Colon
Kidney
Lungs
Melanoma
Ovary
Pancreas
Prostate
Rectum
Stomach
Thyroid
Uterus

Common sites of metastasis
Lungs, liver, bones
Liver, peritoneum, lungs
Lungs, liver, bones
Adrenal gland, liver, lungs
Lungs, skin/muscle, liver
Peritoneum, liver, lungs
Liver, lungs, peritoneum
Bones, lungs, liver
Liver, lungs, adrenal gland
Liver, peritoneum, lungs
Lungs, liver, bones
Liver, lungs, peritoneum

Table 2.1.Common Metastasis Sites by Cancer Type.

Metastatic cancers are particularly problematic because they are difficult
to detect and diagnose. Once circulated, metastatic cancer cells can lie dormant
for long periods of time before growing into a clinically detectable tumor, and
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metastatic disease may be found before, at the same time as the primary tumor, or
much later.12 If the metastatic tumor is detected first, it is characterized and used
to identify the primary cancer. As with primary tumors, therapy for metastatic
cancer usually involves chemotherapy, radiation therapy, hormone therapy,
surgery, cryosurgery, or a combination of therapies.12 However, current therapies
are less effective at treating metastatic cancers, and combined with the increased
difficulty in detecting and treating metastatic cancer, most cancer deaths are due
to metastatic disease instead of primary tumors.10 Discovering ways to image
these metastatic tumors, along with the primary ones, is hence the crucial step in
combating cancer more effectively in our society.
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3

Vitamin B12 (B12)

3.1 B12 Structure
B12, also known as cobalamin, is one of the eight B vitamins.14 Once
described as “nature’s most beautiful cofactor,”15 B12 is a rare example of an
organometallic compound in nature, and it is the only vitamin to possess a stable
metal-carbon bond. In 1964, Dorothy Hodgkin won the Noble Prize in Chemistry
for solving the crystal structure of the vitamin.16

Figure 3.1 shows the molecular structure of the vitamin.1 B12 contains a
six coordinate cobalt(III) atom that is encircled by a tetradentatecorrin ring, a 5,6dimethylbenzimidazole with a phosphoribose unit termed the α-ligand, and a
variable group termed the β-ligand positioned above the plane of the ring. This
group can be a cyano, hydroxyl, methyl, or an adenosyl group.17 B12 supplements
are typically sold as cyanocobalamin, but this biologically inactive form can be
converted into the biologically active forms that carry either a methyl group or a
d’-deoxadenosyl group. Like all of the B vitamins, B12 is classified as highly
water-soluble (10.2 mg/mL).17
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Figure 3.1. Structure of B12, which includes a cobalt(III) bound to a variable
group (R= cyano, methyl, adeosyl, or hydroxyl), a tetradentate corrin ring,
and a 5,6-dimethylbenzamidazole phosphoribose moiety.

3.2 B12 Function
B12 serves as a cofactor for two distinct enzymatic processes.18 In the
cytoplasm, it is required by methionine synthase to convert homocysteine to
methionine through a methylation reaction that is married to nucleotide
synthesis.18 Methionine is an essential amino acid. In the mitrochondrion, it is
required by methylmalonyl-CoA mutase to convert L-methylmalonyl-CoA to
succinyl-CoA in the metabolism of fatty acids.18
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The devastating effects of B12 deficiencies demonstrate how essential the
vitamin is to all cells in the body.18 Moderate B12 deficiencies may occur as a
result of limited dietary access or well as medical conditions that result in poor
absorption and impaired transportation and metabolism of the vitamin,19and
deficiencies commonly occur in individuals who do not consume animal products,
in infants, and in the elderly.20

B12 deficiencies present with neurological symptoms, such as confusion,
headaches, and depression, and with gastrointestinal symptoms, such as nausea,
vomiting, and loss of appetite.18Additional symptoms include paleness, weakness,
and fatigue.18 Chronic or complete inability to uptake the vitamin leads to
degeneration of nerve fibers, or pernicious anemia, which confers permanent
neurological damage.18

3.3 B12 Uptake Pathway
Although mammalian cells require B12 for metabolism and growth, this
essential cofactor must be obtained from external sources; therefore, mammals
have evolved a selective uptake pathway that protects B12 from proteolytic
degradation in the stomach and maximizes absorption and delivery of B12 to the
cells that require it. This human B12 uptake pathway, shown as a scheme in
Figure 3.2, includes three known transport proteins: intrinsic factor,
transcobalamin, and haptocorrin.

9

Figure 3.2. Dietary uptake pathway for B12. Abbreviations used are defined
as: (HC) haptocorrin; (IF) intrinsic factor; (CB) cubilin; (Am) amnionless;
(MRP1) multi-drug resistance protein 1; (MG) megalin; (TCII)
transcobalamin II; (CD320) transcobalamin II receptor.

3.3.1

Haptocorrrin (HC)

When a dietary source of B12 is ingested, it binds to HC, a heavily
glycosylated protein, in the mouth.18 In humans, HC is found in saliva, breast
milk, and plasma.18 HC remains bound to B12 and carries it through the upper
gastrointestinal tract, protecting it from degradation via hydrolysis in the acidic
environment of the stomach.18
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3.3.2

Intrinsic Factor (IF)

When the HC-B12 exits the stomach and enters the duodenum, pancreatic
enzymes degrade HC. The freed B12 binds to IF, a protein that is excreted by the
gastric mucosa and the pancreas. Unlike HC, IF is not degraded by the pancreatic
enzymes due to its heavy glycosylation.18 The IF-B12 complex is transported
through the intestine to the terminal ileum, where it is taken up into enterocyte
cells by a complex composed of cubulin and amnionless known as the cubam
receptor. This process is receptor-mediated endocytosis. In the ileal enterocyte,
the cubilin-bound IF-B12 is broken down to give free B12, which is released into
the bloodstream through the basolateral side of the cell by the ABC transporter
MRP1.18

IF is critical because it transports B12 to the ileal transport receptor,
cubam; the cubam receptor does not bind free B12, only the IF-B12 complex.
Medical conditions such as autoimmune attack of the parietal cells or inborn
errors of IF protein production demonstrate the importance of IF for B12
absorption, as these conditions result in a complete lack of B12 absorption and
pernicious anemia.18

3.3.3 Transcobalamin (TCII)
Once in the plasma, free B12 binds to either TCII or HC, though the
circulating TCII is responsible for transporting B12 to the cells of the body that
require it. These cells take up the TCII-B12 through the transmembrane CD320
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protein, a member of the LDL receptor family, which binds only B12-bound TCII
(holo-TCII). This receptor is present on the cell surface in virtually all tissues21
and is expressed in proportion to the rate at which cells are proliferating.22 Upon
receptor-mediated endocytosis, the TCII-B12 is broken down in the acidic
environment of the lysosome and free B12 is released into the cell for subsequent
methylation or adenosylation and use in the cell.

3.4 Using B12 as a Probe for Cancer
Due to several inherent properties of both cancer cells (as reviewed
above), the vitamin, B12 is ideal to use to target cancer cells for the delivery of
imaging agents with minimum background uptake and harm to the host organism.

3.4.1

Increased TCII Receptors

Ideal cancer diagnostics therapeutics are those that selectively affect
cancer cells but leave normal tissues unharmed; as such, it is important to identify
and exploit characteristics of cancer cells that distinguish them from healthy cells.
One such characteristic is the increased expression of vitamin receptors. In
particular, it has been shown that the expression level of the receptor for the TCII,
the CD320 receptor, is related to the rate at which the cell is growing and
dividing.22 Alberto et al. showed that rapidly growing and dividing cancer cells
require excessive amounts B12, and aggressive tumors have a high density of these
CD320 receptors.23 It is hypothesized that the increased expression of the CD320
receptor helps cells obtain B12 which is required for the biosynthesis of
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nucleotides for increased cell proliferation.18 This finding shows that the B12
pathway can be exploited to offer a tropism for cancer cells for the targeted
delivery of imaging agents or therapeutics to rapidly growing tumors.

3.4.2

De Novo Expression of HC

Certain cancer cell lines express membrane-bound HC de novo.1 Unlike
the other transport proteins intrinsic factor and transcobalamin, HC binds B12 and
B12 fragments.18 The physiological role of HC is not yet fully known.18 Waibel et
al. analyzed HC expression in different tumor types and normal tissues,
demonstrating strong HC positivity in seminoma of the testis, breast cancer, lung
cancer, sarcoma, ovarian cancer, skin cancer, thyroid cancer, uterine cancer, and
kidney cancer, among others.1 By contrast, strong HC positivity of benign tissue
was exclusively found in the liver. As a unique property of cancer cells, the de
novo expression of HC in these specific tumors makes them attractive targets for
B12 probes that would bind to the selectively expressed HC.1

3.4.3

Biocompatibility

B12 probes, which exploit the vitamin’s supply route to target regions of
extreme cell growth, are ideal due to high solubility in aqueous in vitro and in
vivo conditions and a lack of toxicity dangers to the host.17 There are no known
cases of cytotoxicity associated with B12.1 In addition, because B12 is so essential,
the uptake pathway is unlikely to be modified by mutation, suggesting that this
vitamin-based probe would find long-term use in the field.1
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3.4.4

Conjugation Sites on B12

The B12 molecule offers several sites for conjugation chemistry, including
the cobalt metal center, the 5,6-dimethylbenzimidazole phosphoribose unit, and
the propionamide side chains.1 The conjugation site was selected to minimize
interference with B12’s ability to bind with its transport proteins, ensuring that the
probe would be recognized, transported, and internalized properly. Thus, instead
of derivatizing the cobalt metal center or functionalizing the amides, conjugations
were carried out at the 5’ hydroxyl group of the phosphoribose moiety of B12.
This site was previously shown to be reactive in a coupling reaction with 1,1dicarbonyl-di-(1,2,4-triazole) (CDT) coupling agent, and conjugates retained
binding with IF and TCII.24
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4

Fluorescence Imaging for In Vitro Imaging

4.1 Rhenium
The radioisotope of technetium, 99m-technicium (99mTc), has been
described as the “medical isotope of choice for nuclear imaging.”25 Produced by
the beta decay of 99Mo in a commercial generator,

99m

Tc has a half-life of ~6

hours, which is long enough to be useful in diagnostic procedures but not so long
as to be dangerous to the patient.25 However, there is no stable isotope of
technetium, so scientists use “cold” rhenium studies as a surrogate test that can
then be translated to technetium for the development of a nuclear imaging
diagnostic probe.

As congeners of group 7, technetium and rhenium have similar physical
properties and coordination chemistry. While 186Re(I) is not a commonly used
fluorophore, is has a distinct excitation and emission profile, and the fluorescent
186

Re(I) can be used in vitro to test the efficacy of ligands for direct translation to

radioactive 99mTc for use in vivo. Rhenium (and technetium) fac-tricarbonyl
bearing polypyridyl ligands have been developed and studied for use in the field
of cellular imaging.25,26,27

4.2 Utility of a B12-based Fluorescent Probe
A fluorescent B12-based probe would find use in a number of research
settings. In the Doyle lab, such a construct could be used to investigate the
association and internalization of B12 based therapeutics and imaging agents in a
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cellular system prior to in vivo models. Positive uptake would suggest that
specific chemical modifications to B12 did not critically interfere with transport
protein binding and recognition and that the B12 conjugate was recognized and
internalized by living cells. In research groups around the world, a fluorescent
B12-based probe would allow for the preliminary screening of cultured cell lines
to confirm the presence of certain receptors that are important in the B12 uptake
pathway, such as cubilin. Finally, for laboratories that are studying the differential
expression of these receptors in varied tissue samples, such a probe would provide
a confirmation of the receptor on the cellular level—functionality that cannot be
obtained from biochemical methods such as reverse transcriptase polymerase
chain reaction (RT-PCR) or Western blot.

4.2.1

Previous B12-based Fluorescent Probe Constructs

The first generation fluorescent B12-basedprobe for use in vitro studied in
the Doyle lab was designed to target cubilin expressed in cancerous cells. This
probe, B12-BQBA-[Re(CO)3], incorporated a ligand N,N-bis(quinolinoyl)
(BQBA) to chelate the Re(I).26 Doyle et al. synthesized, purified, and
characterized the probe, and then screened placental choriocarcinoma BeWo cells
to show uptake of B12-BQBA-[Re(CO)3] via an IF-cubilin receptor mediated
endocytosis mechanism.26 This work was published in 2009 in the Journal of
Medicinal Chemistry.
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4.3 B12-[Re(CO)3]-Thiazole
The utility of the first generation B12-BQBA-[Re(CO)3] probe was
severely limited by its poor solubility in aqueous solvents, and the second
generation probe was designed to be more water-soluble and thus more useful in a
water-based cell system.27 Instead of the BQBA, a bifunctionalthiazole ligand
that was first described by the Valliant group was chosen based on its ability to
both chelate the Re(I) and offer an amino group for coupling with B12.27 This
ligand was also expected to be more polar, and thus, more water-soluble. The
final compound, a water-soluble B12-Re(I) probe incorporating the thiazole linkerchelator moiety, was used to demonstrate the presence of cubilin in A549 lung
cancer cells. The entire synthetic scheme is shown in Figure 4.1.

Figure 4.1. Synthesis of B12-[Re(CO)3]-Thiazole.
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4.3.1

Synthesis, Purification, and Characterization of 1,1, bisthiazole
(1,4) di-aminobutane

1,1, bisthiazole (1,4) di-aminobutane (1) was synthesized by combining NBoc-1,4-butanediamine (100 mg, 0.53 mmol) and thiazole-4-carboxaldehyde (120
mg, 1.06 mmol) in 5 mL of anhydrous dichloroethane and stirred under N2(g) at
room temperature. After 30 minutes, sodium triacetoxyborohydride (225 mg, 1.5
mmol) was added and the reaction was stirred for an additional 16 hr. The solvent
was removed in vacuo, and the reaction was redissolved in 10% MeOH/10% TFA
in H2O and stirred for 3 hr.

1 was purified by RP-HPLC using an analytical C18 column (Agilent
Eclipse XDB-C18 9.4 mm X 250 mm, 3 µm particle size) on an Agilent 1100
series instrument with a quaternary pump and UV detection at 254 nm. The
solvents for purification included (A) 0.1% TFA/water and (B) 0.1% TFA/MeCN,
and the flow rate was 1 mL/min. The method was a gradient of 0-20% B over 5
min, followed by an increase to 40% B over another 4 min. Under these
conditions, 1 eluted with a Tr of 3.4 min. The yield of 1 was 60%.

Purity of 1 was confirmed via 1H NMR and MALDI-ToF/MS. An 1H
NMR spectra, taken in deuterium oxide (D2O) at 300 MHz, confirmed the
proposed structure of 1, showing 1H NMR peaks (in δ): 9.06 s, 2H; 7.83 s, 2H;
4.57 m, 4H; 3.24 t, 2H; 3.00 t, 2H; 1.92 m, 2H; 1.67 m, 2H. MALDI-ToF/MS
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showed a peak consistent with 1 at 283.15 m/z, the expected M[H]+ value of
283.1 amu.

4.3.2

Synthesis, Purification, and Characterization of Re(CO)3-1,1,
bisthiazole (1,4) di-aminobutane complex

The purified ligand 1 was labeled with rhenium to give Re(CO)3-1,1,
bisthiazole (1,4) di-aminobutane complex (2). 1 (20 mg, 0.07 mmol) and
Re(H2O)3(CO)3Br (3 mg, 0.07 mmol) were dissolved in MeOH and refluxed for 3
h. The solvent was removed in vacuo and the residue was redissolved in 10%
MeOH in H2O.

2 was purified by RP-HPLC using an analytical C18 column (Agilent
Eclipse XDB-C18 9.4 mm X 250 mm, 3 µm particle size) on an Agilent 1100
series instrument with a quaternary pump and UV detection at 254 nm. The
solvents for purification were (A) 0.1% TFA/water and (B) 0.1%TFA/MeCN, and
the flow rate was 1 mL/min. The method was a gradient of 0-20% B over 5
minutes, followed by an increase to 40% B over another 4 minutes. Under these
conditions, 2 eluted with a Tr of 5.2 min. The yield of 2 was 73%.

Purity of 2 was confirmed via 1H NMR and MALDI-ToF/MS. An 1H
NMR spectrum taken in deuterium oxide (D2O) at 300 MHz, confirmed the
proposed structure of 2, showing 1H NMR peaks (in δ): 9.57 s, 2H; 7.67 s, 2H;
4.67 m, 4H; 3.8 t, 2H; 2.90 t, 2H; 1.94 m, 2H; 1.70 m, 2H. MALDI-ToF/MS
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showed a peak consistent with 2 at 553.05 m/z, the expected M[H]+ of 553.04
amu.

4.3.3

Synthesis of B12-[Re(CO)3]-Thiazole (2)

2 was coupled to the 5’ hydroxyl of the ribose group of B12 via 1,1’-carboyldi-(1,2,4-triazole) (CDT) coupling to give B12-[Re(CO)3]-Thiazole(3). B12 (10
mg, 0.006 mmol) and CDT (2 mg, 0.010 mmol) were dissolved in dry DMSO and
heated to 40°C for 1 hr under N2(g) to activate the hydroxyl group for coupling
with an amino group. 2 (4 mg, 0.007 mmol) was added to the reaction and the
reaction was left stirring under N2(g) overnight (Figure 4.2). After 16 hr, the
reaction was precipitated using acetone and diethyl ether to give a deep red
precipitate that was redissolved in 10% MeOH in H2O.

Figure 4.2. CDT-Coupling of 2 to B12.
3 was purified by RP-HPLC using an analytical C18 column (Agilent
Eclipse XDB-C18 9.4 mm X 250 mm, 3 µm particle size) on an Agilent 1100
series instrument with a quaternary pump and UV detection at 254 nm. The
solvents for purification included (A) 0.1% TFA/water and (B) 0.1%TFA/MeCN,
and the flow rate was 1 mL/min. The method was a gradient of 0-20% B over 5
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minutes, followed by an increase to 40% B over another 4 minutes. Under these
conditions, 3 eluted with a Tr of 7.3 min (Figure 4.3). The yield of 3 was 13%.

Figure 4.3. RP-HPLC trace. 3 elutes at 7.3 minutes.
Purity of 3 was confirmed via 1H NMR and MALDI-ToF/MS. An 1H
NMR spectrum, taken in deuterium oxide (D2O) at 300 MHz, confirmed the
proposed structure of 3, showing 1H NMR peaks (in δ): 9.19 d, 2H; 7.74 s, 2H;
7.24 s, 1H, 7.04 s, 1H; 6.48 s, 1H; 6.26 s, 1H, 6.02 s, 1H. MALDI-ToF/MS
showed a peak consistent with 3 at 1907.24 m/z, the expected M+[-CO] of 1907
(Figure 4.4 and 4.5).
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Figure 4.4.MALDI-ToF/MS of 3, showing expected mass at 1907 amu for the
M[H]+.

Figure 4.5. The calculated (left) and experimental (right) isotopic patterns of
3, without one CO group, are equivalent and consistent with M[H]+.
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4.4 Fluorescent Studies of 3
Fluorescence spectroscopy was carried out on a Horiba JobinYvon
(Kyoto, Japan) FluoroMax-4 spectrofluorometer in PBS buffer. 3 had an
absorption maximum of 466 nm (Figure 4.6).

The fluorescence emission

spectrums of 3 were measured with excitation at 458 nm (Figure 4.7) and 488 nm
(Figure 4.8).

Figure 4.6. Excitation wavelength scan (200-600 nm) for 3.
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Figure 4.7. Emission spectrum of 3 upon excitation at 458 nm.

Figure 4.8. Emission spectrum of 3 upon excitation at 488 nm.

Compared to the unconjugated rhenium-labeled fluorescent tag 2, the full
probe 3 showed weaker fluorescence intensity. The likely cause for the decrease
in fluorescence upon conjugation with B12 is quenching by the B12 molecule.28
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When IF was added, the fluorescence improved significantly in terms of intensity
and emission maximum, suggesting that IF binding to 3 relieves the quenching
effect. Upon IF addition, a 15-fold increase in fluorescence intensity was
observed, and the emission maximum blueshifted ~30 nm from ~555 to ~525 nm.

The quenching nature of B12 was further confirmed by adding excess B12
to IF-3. A decrease in fluorescence was observed when a 100-fold excess of pure
B12 was added to IF-3, as the excess B12 resulted in a loss of binding of IF to 3.
Figure 4.9 shows the fluorescent emission spectrum of 3, IF-3, and IF-3 with 100x
excess of free B12. When bovine serum albumin (BSA) was added as a control,
the fluorescence intensity increased only 5% and the emission maximum did not
shift (Figure 4.10).

25

Figure 4.9. Fluorescent emission spectrum of 3 (blue), IF-3 (red), and IF-3
with 100-fold excess of free B12(green), demonstrating a quenching effect by
excess B12.

Figure 4.10. Fluorescent emission spectrum of 3 (blue) and bovine serum
albumin (BSA)/3 (red). Unlike IF, the addition of BSA did not alter the
emission maxima, suggesting that 3 can be used to follow IF binding in a
facile manner.
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The quenching issue observed for free 3 is not a concern for in vitro or in
vivo experiments because 3 must be bound to IF in order to be recognized and
internalized by the cubilin receptor; IF binding relieves the quenching and
maximizes the fluorescent signal. However, the dramatic effects of IF binding on
the photophysical properties of 3 could be exploited to monitor binding of IF to 3
in other studies.

4.5 Screening of A549 Lung Cancer Cells with IF-3
After fluorescence studies, IF-3 was added to A549 lung cancer cells and
studied via confocal microscope to look for uptake of IF-3.

4.5.1

Cell lines and culture conditions

The A549 lung cancer cell line (ATCC CCL-185) was cultured in Millipore
250 mL culture bottles with vented lids and incubated in a VWR mammalian
incubator at 5% CO2 and 95% humidity, conditions meant to mimic physiological
conditions. Cells were grown in F-12K media supplemented with penicillin (10
000 U), 10 mg mL-1 streptomycin, and 10% fetal bovine serum (FBS). Prior to
testing, cells were passed in this F12K media and penicillin–streptomycin
solution.

For confocal experiments, 200,000 cells were plated onto MatTek 35 mm
glass bottom culture dishes and incubated overnight. The media was then replaced
with phosphate-buffered saline (PBS) containing 100 µmol of IF-3 and incubated
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for 1 hour. After incubation, the cells were washed with PBS to remove any
excess and unbound IF-3.

4.5.2

Confocal Microscopy

Cells were viewed under a Zeiss LSM 710 Pascal confocal microscope
with Zen 2009 image analysis software equipped with argon ion and HeNe lasers.
Fluorescence was observed with a 63X objective with an excitation at 458 nm and
488 nm lasers. The laser power was set to 20% 458 nm and 35% 488 nm. The
signal was detected using a 493–630 nm filter, with the master gain set to 281 and
the digital game set to 9.86 with a pinhole of 49 µm.

Initially, when the cells excitation was carried out by either a 458 nm laser
or a 488 nm laser, the confocal microscopy conditions needed to detect the weak
fluorescent signal of IF-3 also produced natural cellular fluorescence in A549
control cells. This background autofluorescence is thought to be from molecules
naturally present in the cell, such as flavins, porphyrins, and other aromatic
compounds.29 Because it was difficult to distinguish the autofluoresence from the
fluorescent signal of IF-3, excitation was attempted at both 458 nm and 488 nm
simultaneously. This dual-excitation produced a maximized signal, kept both
pinhole and detector gain low, and did not produce background fluorescence in
the control cells. The control cells are shown in Figure 4.11. These conditions
successful eliminated the potential for a false positive result.
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Figure 4.11. 63X magnification of A549 cell controls (i.e. no addition of IF-3)
under matching confocal microscope test conditions.

Under these conditions, it was shown that the IF-3 was internalized in
A549 cells with clear cytoplasmic localization (Figure 4.12). No localization in
the nucleus was observed.
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Figure 4.12. 63x magnification image of uptake of IF-3 in A549 cancer cell
line with dual excitation at 458 and 488 nm at room temperature (compare to
Figure 4.11 control). IF-3 is localized in the cytoplasm.

In order to confirm that the IF-3 was targeting the cubilin receptor and that
the observed uptake was due to receptor-mediated endocytosis, the experiment
was repeated at 4 °C. At 4 °C, uptake due to receptor mediated endocytosis
would be halted, while uptake due to passive diffusion would not be affected.
The cells were pre-chilled for 30 minutes, after which time a chilled solution of
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IF-3 was added. The cells were incubated at 4 °C for 1 hr and visualized via
confocal microscopy under the same conditions. The cells showed no
internalization of the IF-3, but cell surface binding was still observed—an
expected result, as receptor recognition is not lost at low temperature (Figure
4.13).

Figure 4.13. 63x magnification image showing uptake studies of IF-3 in A549
cells performed at 4 °C. No internalization was observed.

Based on the quenching effect of free B12, a B12 challenge experiment was
determined to be of limited utility. Excess B12 was expected to quench the
fluorescence of IF-3, thereby potentially yielding a false negative which would be
difficult to distinguish from blocked uptake.
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4.6 RT-PCR and Western Blot Analyses
Expression of cubilin was independently confirmed by reverse
transcriptase polymerase chain reaction (RT-PCR) and western blotting through
collaboration with the University of Aarhus in Denmark.

4.6.1

RT-PCR

RT-PCR was carried out to confirm the expression of cubilin on the level
of mRNA. RNA from A549 cells was extracted using QiagenRNeasy mini kit as
per manufacturer’s instructions (Qiagen). The ‘One step RT-PCR kit’ (Qiagen)
was used. Total PCR reaction volumes were 25 mL and reaction included: 200 ng
of RNA template, 5x Buffer [Tris.Cl, KCl, (NH4)2SO4, 12.5 mM MgCl2, DTT; pH
8.7], 1xQ solution, 0.4 mM of each deoxynucleotide triphosphate (dNTP), 15
pmol of each primer, 1.0 µL enzyme mix (Omniscript and Sensiscript Reverse
Transcriptases, HotStartTaq DNA polymerase). Non-template controls were
performed for each set of primers and template. The reverse transcription and
amplification were carried out under the following incubation program: 30 min at
50 °C, 15 min at 95 °C, 35 cycles at 94 °C for 1 min, 50 °C for 1 min, 72 °C for 3
min, and finally 10 min at 72°C. Amplification products (20 µL) were analyzed
on a 2% agarose gel and visualized using SybrGreen. The sizes of the separated
bands were estimated by comparison with a 100 bp DNA marker. Cubilin mRNA
was detected in A549 cells by RT-PCR.
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4.6.2

Western Blot

A western blot was carried out to confirm the expression of cubilin on the
protein level. A549 cells were lysed on ice in PBS buffer (10 mm NaH2PO4, 150
mm NaCl, 6 mm CaCl2) including 1% Triton X-100 (Merck) and complete mini
EDTA-free protease inhibitor cocktail tablets (Roche Diagnostics), pH 7.4.
Protein samples were then boiled in sample buffer (20 mm Tris, pH 6.8, 5% SDS,
17.4% glycerol and pyronin Y) and separated by sodium dodecyl sulpatepolyacrylamide gel electrophoresis (SDS-PAGE) using 3-8% acrylamide gels.
After the gel electrophoresis, proteins were blotted onto a
polyvinylidenedifluoride membrane. Immunoblotting was performed using anticubilin antibody (at 2 µg/ml) as primary antibody and alkaline phosphataseconjugated anti-rabbit (1:50,000). Proteins were visualized using 5-bromo-4chloro-3-indolyl-phosphate-nitro blue tetrazolium.
Cubilin protein was detected by western blot, although the level of
expression was low overall, compared to the previously characterized cubilin
expression in the Brown Norway rat yolk sac cell line BN16. The cubilin protein
detected in A549 cells was compared with purified cubilin control protein purified
by IF-B12-affinity chromatography from human kidney. The protein from A549
cells appeared to be full length and of the same size as the kidney control protein.
The Western blot is shown in Figure 4.14.
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Figure 4.14. Western blot analysis of lysate of A549 cells. Lane 1: lysate of
A549 cells. Lane 2: control cubilin protein purified from human kidney by
IF-B12 affinity chromatography.

This work was published in Chemical Communications in 2011 in a paper
titled “A water soluble vitamin B12-Re(I) fluorescent conjugate for cell uptake
screens: use in the conformation of cubilin in the lung cancer line A549.v
Chemical Communications is the premier journal of the Royal Society of
Chemistry.

4.7 Future work: Translation of in vitro Probes for in vivo use with Re(I) to
99m

Tc
The Re(I) -B12 probe can be readily translated to in vivo studies with

minimal modifications to the overall ligand and conjugation process. The Re(I)
coordinated to the thiazole ligand can be readily switched to a radioactive
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derivative containing 99mTc and studied using single photon emission computer
tomography (SPECT) scanning.30 With ideal nuclear properties for clinical
application and commercial availability, 99mTc is used in most diagnostic
procedures today, and this system could be used as a targeted therapeutic in
nuclear medicine.25

The functional role cubilin in lung cancer cells is unknown, and the
finding of cubilin in these cells warrants further investigation. Looking forward
into the development of therapeutics, these results on the presence of cubilin in
lung cells also suggests the possibility of targeting drugs in lung cancer cells in
vivo by aerosolizing B12-drug conjugates—a substantial advance in cancer
treatment.

35
5

Positron-Emission Topography In Vivo Imaging

5.1 PET Scanning
Within nuclear medicine, there exist two main non-invasive imaging
techniques: single photon emission computer tomography (SPECT) and positronemission tomography (PET) scanning.25 Of the two, PET scanning provides
higher resolution and sensitivity.25 PET uses a radioactive element, such as
fluorine-18, oxygen-15, carbon-11, or nitrogen-13, which decays through the
emission of a positron that collides with an electron to produce gamma rays.
These gamma rays are detected and compiled by a PET scanner and used to
reconstruct a computerized image of the body. Clinically, the most commonly
used radioactive imaging agent is fluorine-18 tagged to fluorodeoxyglucose
(FDG), and the use of PET technique has grown since the late 1990s, when the
FDA approved FDG and PET scanners were made mobile.31

As a diagnostic tool, PET scanning is valuable because it can be adjusted
to detect and monitor a variety of physiological processes in various organs and
parts of the body.32 The increased sensitivity of PET scanning allows for the use
of doses of radiolabelled imaging agents that are too small to cause
pharmacological effects.32

5.2 Copper-64
In the growing field of molecular imaging, research has focused on
developing, screening, and testing radiolabelled target agents for clinical use. In
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particular, attention has been focused on PET imaging agents incorporating
copper-64, (64Cu), a radioactive isotope of copper.32 64Cu has a half-life of 12.7
hours, which is long enough to allow for regional distribution but is not so long
that the patient is at risk for prolonged radiation exposure.32 In addition, it is
readily synthesized on a cyclotron and a number of different ligands can be
adapted for its use.32

However, copper is an important metal physiologically, and copper
homeostasis is tightly regulated by both intracellular and extracellular copperbinding molecules. Therefore, it is essential that any radiolabeled copper species
does not disturb other copper-dependent processes in the body. A viable copper
chelate for biological use must be both thermodynamically stable and kinetically
inert to prevent the release of the copper metal.33

Many of the current radiopharmaceuticals incorporating copper
radioisotopes are bifunctional chelators that provide both a site for stable copper
labeling and also chemical groups to covalently attach to biologically active
molecules.34 The chelators most commonly utilized for labeling copper
radionuclides to biomolecules are analogues of 1,4,8,11-tetraazacyclotetradecane1,4,8,11-tetraacetic acid (TETA).34 However, these “non-bridged” macrocyclic
ligands show limited in vivo stability.34 Recent literature reports a higher degree
of kinetic stability using bicyclic tetraazamacrocycles, the ethylene “cross-
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bridged” cyclam (CB-cyclam) derivatives,34 which showed no decomposition and
rapid clearance from all tissues.34

5.3 B12-ethylenediamine-1,4,7,10-tetraazacyclododecane-N’,N’’,N’’’,N’’’’tetraacetic acid (B12enDOTA)
Because these copper radionuclides covalently attached to biological
molecules hold such great promise for diagnostic imaging and targeted
radiotherapy, a B12-based probe was constructed by conjugating B12 with a linker
molecule, ethylenediamine (en), and a metal-chelating macrocyclic ligand,
1,4,7,10-tetraazacyclododecane-N’,N’’,N’’’,N’’’’-tetraacetic acid (DOTA). The
resulting compound, B12enDOTA (1), offers a site for the labeling to produce a
radio labeled probe. 1 was purified by a two-step method involving an analytical
anion exchange column and a C18 analytical column on reverse phase HPLC
(RP-HPLC). The purity of 1 was confirmed by nuclear magnetic resonance
spectrometry (1H NMR) and matrix-assisted laser desorption/ionization-time of
flight mass spectrometry (MALDI-TOF MS). In collaboration with the
Washington University Medical School in St. Louis, Missouri, 1 was labeled with
64

Cu. Given the strong success of my initial 64Cu-labeling experiments—showing

100% radiolabeling—the labeled analogue of 1 was tested in vivo in a mouse
model.
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5.3.1

Synthesis of 1

The first step of the synthesis was to functionalize the 5’hydroxyl group
on the ribose moiety of B12 to an amine group for future peptide coupling
reactions with the macrocyclic ligand. B12 (cyanocobalamin, 100.0 mg, 73.8
mmol) was activated with 1.45 equivalents of 1,1’-carboyl-di-(1,2,4-triazole)
(CDT) (17.6 mg, 107.3 mmol) in 6 mL dry dimethyl sulfoxide (DMSO) at 40 °C
for 1 hr under N2 (g). Ethylenediamine (en) (4.59 µL, 68.7 mmol) and
triethylamine (TEA) (9.59 µL, 68.8 mmol) were diluted in 1 mL dry DMSO. The
CDT-activated B12 was added drop-wise over 30 min to the en solution. The
reaction solution was stirred under N2 (g) for 3 hr at 40 °C. After 3 hr, the reaction
product was crashed out of DMSO using 4:1 diethyl ether/acetone solution, spun
down at 4000 rpm for 10 min, and dried in vacuo overnight.

In the second synthesis reaction, the carboxylic acid arm of the
macrocyclic ligand (DOTA) was conjugated to the free amino group of the B12en
conjugate via peptide coupling to give 1. Because DOTA offers reactive four
carboxylic acid arms, the DOTA was added in two equivalents excess to
encourage the formation of a 1:1 B12en:DOTA conjugate, assuming a yield of
100% for the B12-ethylenediamine (B12en) reaction, (106 mg, 73.8 mmol).

DOTA was activated using the water soluble 3(ethyliminomethyleneamino)-N,N-dimethyl-propan-1-amine (EDC) coupling
agent with N-hydroxysulfosuccinimide (sulfo-NHS) to increase coupling
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efficiency. Two equivalents of DOTA (59.4 mg, 0.147 mmol) and 2.5 equivalents
of sulfo-NHS (47.9 mg, 0.221 mmol) were dissolved in 1 mL 100 µM sodium
phosphate (pH 6.5). EDC (30.9 mg, 0.162 mmol) was dissolved separately in 50
µL of the same buffer and added drop-wise over 20 min to the DOTA and sulfoNHS solution. After the solution was allowed to activate at room temperature for
30 min, B12en was dissolved in 2 mL 100 µM sodium phosphate (pH 6.5) and was
added to the activated DOTA. The reaction was left stirring overnight at room
temperature. Figure 5.1 shows the entire synthesis of 1.

Figure 5.1: Schematic of the Synthesis of 1

5.3.2 Purification of 1
A two-step purification scheme was to first separate 1 from unreacted B12
and B12en, and second from other oligomers that formed. Both purifications were
performed on RP-HPLC. The first used a Zorbax Sax analytical anion exchange
(ANX) column (4.6 mm x 250 mm) on an Agilent 1200 series instrument with a
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quaternary pump and UV detection at 254 nm. Solvents for elution included (A)
water and (B) 0.5 M sodium chloride. At a flow of 1.0 mL/min, the gradient was
(1) 100% A for 6 min then (2) 100 % B for 22 min (Figure 5.2).

Figure 5.2. ANX Purification of 1 by RP-HPLC, with elution of 1 beginning
at 13 min.

Each peak was collected and characterized by MALDI-ToF/MS, which
suggested that the ANX HPLC peak with a retention time of 13–14.5 min was 1
(showing major MALDI-ToF/MS peaks at 1801.7 m/z, indicative of [M+–CN]).
However, this peak also showed MALDI-ToF/MS peaks at 2770.1 m/z, and
3198.3 m/z, suggesting that other impurities had eluted with the 1, including
B12enB12 and B12enDOTAenB12. The target peak was dried in vacuo and
redissolved in H2O (0.1 % TFA) to uniformly protonate the three unbound
carboxylic acid arms of DOTA in preparation for a second C18 RP-HPLC
purification to isolate 1 from the ANX impurities.
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Figure 5.1. C18 Purification of B12enDOTA (1) by RP-HPLC, with elution of
B12enDOTA (1) at 7.17 min.
The second purification was performed using a Zorbax C18 analytical
column (42 mm x 10 mm) at a flow rate of 1.0 mL/min. Solvents for elution
included (A) H2O (0.1 % TFA) and (B) MeCN (0.1% TFA). The method was a
linear gradient of 10% B to 20% B over 10 min. Under this method, 1 showed a
Tr= 7.17 min (Figure 5.3). This peak was collected and dried in vacuofor
characterization. The yield of 1 was ~11% based on B12.

5.3.3

Characterization of 1

Purity of 1 was confirmed via 1H NMR and MALDI-ToF/MS. An 1H
NMR spectra, taken in deuterium oxide (D2O) at 300 MHz, confirmed the
proposed structure of 1 and showed a downfield shift of the ethylene protons of
DOTA. 1H NMR peaks (in δ) included: 7.306 (1H, s), 7.126 (1H, s), 6.517 (1H,
s), 6.361 (1H, s), and 6.111 (1H, s) (Figure 5.4).
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Figure 5.4. 1H NMR of 1 in D2O at 300 MHz.
The MALDI-ToF/MS of the HPLC peak at Tr= 7.17 min contained a peak
at 1801.7 m/z, consistent with the theoretical molecular mass of [M+] = 1827.9
minus the cyano group of cyano-B12, [M+–CN] = 1802.08 m/z (Figure 5.5). The
isotopic distribution pattern of this peak was consistent with that of the calculated
isotopic distribution pattern of 1, based on the formula C82H120CoN20O22P (Figure
5.6).
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Figure 5.5. MALDI-ToF/MS showing a peak at 1802 m/z consistent with 1
without the cyano group of B12.

Figure 5.6. Calculated (left) and experimental (right) isotopic patterns of 1,
without the cyano group of B12, are equivalent.
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The RP-HPLC trace showed an impurity, represented by a second peak
with Tr=5.11 min. This peak was confirmed by MALDI-ToF/MS to be 1 with a
proton captured within the DOTA macrocycle, 1801.1 m/z. An experiment at
65°C confirmed the proton adduct theory, as the peak disappears in the RP-HPLC
trace when the proton is driven out of DOTA in higher temperatures.

5.3.4

Radiolabeling of 1 with 64Cu for In Vivo Uptake Studies

A pure sample of 1 was sent to Dr. Suzanne Lapi and Dr. TayoIkotun of
the Department of Radiology at Washington University in St. Louis, MO, for
radiolabeling. 1 was labeled with 64Cu to give 64Cu-B12enDOTA (2). At 23 °C,
both 1 and the impurity at Tr= 5 min (discussed in section 5.3.3) were labeled
(Figure 5.7). 1 was labeled at 95% efficiency by radiation counts.

At 65 °C, 1 was labeled with 64Cu at 100% efficiency, and the impurity
was no longer seen. As suggested above, it is likely that upon heating, the proton
was driven out of the DOTA macrocycle and replaced by 64Cu (Figure 5.8).
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Figure 5.7. RP-HPLC chromatograph following 64Cu labeling of 1 at 23 °C.

Figure 5.8. RP-HPLC instruments chromatograph following64Cu labeling of
1 at 65 °C. At 65 °C, the impurity at Tr= 5 min disappears and 100% labeling
is achieved.
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5.3.5

Preliminary In Vivo Characterization of 2 in a Mouse Model

2 was tested on two different cell lines transplanted into mice. The first,
B16 mouse melanoma cells, were chosen because they are commonly used to
study in vivo cancer targeting agents. In addition, these cells express membraneassociated HC de novo.1 The second, human pancreatic cancer PaCa-2 cells, were
chosen because have been shown to express transcobalamin CD320 receptor for
TCII.35 In combination, the B16 and PaCa-2 cell lines allowed for the study of
the specific HC and TCII B12 uptake mechanisms, respectfully.

Two groups of mice were placed on a B12 deficient diet over a period of
two weeks and implanted with either B16 or PaCa-2 cells. The cells were
allowed to grow for up to two weeks. 2 was injected intravenously, and the
biodistribution was determined at 6 and 24 h by isolation of mouse organs and
conduction radio counts. The results for the B16 are shown in Figure 5.9, and the
results for the PaCa-2 cells are shown in Figure 5.10.
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Figure 5.9. Biodistribution of radiation counts 6 and 24 h after injection of 2
into mice with B16 cell tumors, which express membrane-bound HC de novo.
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Figure 5.10. Biodistribution of radiation counts 6 and 24 hr after injection of
2 into mice with PaCa-2 cell tumors, which are known to express TCII
receptors.

In both tumor models, 2 showed about a 2% tumor distribution. A tumor
distribution of at least 5% would be ideal. However, at 2% tumor distribution, 2
was successful in visualizing the PaCa-2 tumor. In order to demonstrate that? 2
was targeting the cells through a B12 receptor, excess free B12 was added to
saturate the B12 receptors and block distribution. Figure 5.11 shows the successful
visualization of the PaCa-2 tumor (left) and block of 2 through the addition of
excess free B12 (right).
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Figure 5.11. Left: The PaCa-2 tumor is visualized by intravenous injection of
2. Right: Addition of free B12 blocked delivery of 2, indicated that a B12
receptor had been targeted.

Outside of the tumor, significant levels of radiation were detected in the
liver, kidney, and small and large intestine. The high kidney distribution was
expected due to a) the kidneys’ role in clearing the drug and b) the high amounts
of B12 receptors present in the organ. However, the high distribution in the liver
and intestines warranted further investigation. The high amount of radiation
detected in the liver suggested that free 64Cu had been released from the DOTA
macrocyclein vivo, a phenomena that has been reported in literature.34 In response
to the poor stability of 2, a more stable conjugate incorporating a related ligand
was synthesized (see Section 5.4). The high distribution in the small and large
intestine suggested that the animals were actually re-digesting fecal matter
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containing the cleared radiolabeled drug during the experiment. In order to
prevent this, metabolic cages will be used in future experiments to prevent
ingestion of fecal matter. It is hypothesized that in future experiments,
incorporating the new conjugate and metabolic cages, a tumor distribution of
higher than 2% can be achieved.

5.4 B12en(S)-p-SCN-Bn-1,4,7-triazacyclononane-N,N′,N′′-triacetic acid
(B12enNOTA)
A more stable chelator molecule was selected for a revised probe construct.
A related macrocyclic ligand, 1,4,7-triazacyclononane-N,N′,N′′-triacetic acid
(NOTA), was substituted for the DOTA, to give an optimized compound,
B12enNOTA (3) with a higher expected degree of kinetic stability in regards to
chelating the 64Cu. Thus, trials with 3 were expected to show less radiation in the
liver.

5.4.1

Synthesis of 3

In the interest of maximizing reaction yield, the NOTA ligand was
prepared with a thiocyanate group that is highly reactive with previously prepared
B12en. Mole equivalents of B12en (20 mg, 1.38 x 10–2mmol) and p-SCN-NOTA
(6.21 mg, 1.38 x 10–2mmol) were dissolved in 3 mL of 100 mM sodium
carbonate, pH 10.5, and combined at room temperature. The reaction was left
stirring under air for 16 h (Figure 5.12).
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Figure 5.12. Coupling of B12en to p-SCN-NOTA to give 3. The thiocyanate
group helped increase yield.

5.4.2

Purification of 3

3 was purified by RP-HPLC using an analytical C18 column (4.6 mm X
150 mm, 3 µm particle size) on an Agilent 1200 series instrument with a
quaternary pump and UV detection at 360 nm. The solvents for purification
included (A) 0.1% TFA/water and (B) MeCN, and the flow rate was 1 mL/min.
The method was a gradient of 10-25% B over 0-15 min. Under these conditions,
B12en eluted at about 7 min and 3 eluted at 12.5 min (Figure 5.13). The peak with
Rt= 12.5 was collected and dried in vacuofor characterization. The yield was 95%.
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Figure 5.13. Purification of 3 by RP-HPLC, showing distinct elution of B12en
at ~7 min (red) and elution of 3 at ~12.5 min (blue).

5.4.3 Characterization of 3
The identity of 3 was confirmed by 1H NMR, infrared spectroscopy (IR),
and MALDI-ToF/MS. A 1H NMR was taken in D2O at 300 MHz, giving peaks (in
δ) at: 7.283 (s, 2 H), 7.160 (s, 2 H), 7.096 (s, 1 H), 6.455 (s, 1 H), 6.276 (d, 1 H),
6.00 (t, 1 H).

In the coupling reaction, the isothiocyanate group of the p-SCN-NOTA
would disappear; IR spectroscopy was utilized to look for the absence of the
intense characteristic isothiocyanate stretch at 2125 cm–1. The IR confirmed that
this band was gone, and thus that the original reactant containing the group, the pSCN-NOTA, had fully reacted with the B12en (Figure 14). In MALDI-ToF/MS,
the mass of 3 [M – CN]+ was expected to be 1867 m/z. Figure 5.15 shows a peak
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at 1867.483 m/z, confirming the identity if 3.
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Figure 5.14. IR spectrum of 3, showing a lack isothiocyanate group,
represented by a band at 2125 cm–1.
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Figure 5.15. MALDI-ToF/MS showing a peak at 1867 m/z, consistent with 3
without the cyano group of B12.
5.5 Future Work
It is hypothesized that the tumor distribution of a radiolabeled B12 probe
will be increased by the incorporation of the NOTA ligand and inclusion of
metabolic cages in the animal protocol. The increased stability of the NOTA
chelate for the 64Cu is expected to lower radiation in the liver, while the
prevention of fecal ingestion is expected to lower radiation in the small and large
intestine. These experiments are currently underway in collaboration with Dr.
Lapi and Dr. Ikotun at Washington University.

1900

m/z

55
6

B12 Monocarboxylic Acid Derivatives

6.1 Introduction
While B12-based imaging agents have experimentally labeled tumor tissue
through successful receptor-mediated endocytosis of the TCII-bound B12
conjugate,35 significant background levels of radioactivity were detected in
normal tissue.1 In particular, high uptake is seen in the kidneys and the liver
because these organs are responsible for clearing and storing B12, respectfully.1
High uptake of radiolabeled compounds in the kidney may lead to radiation
toxicity, and the radiation dose to the kidney is often the “dose-limiting” factor for
the clinical use of nuclear medicine.1

However, the highest expression of CD320 is seen in the kidneys, which
poses a problem for the development of B12-based therapeutics. A solution to this
problem would be to knock out the B12 conjugate’s ability to bind with TCII, yet
maintain binding with other important transport proteins. Additionally, Waibel et
al. suggest that a B12-based probe with decreased binding with TCII would clear
from the blood more quickly than the transport protein-bound form, decreasing
overall systemic toxicity.1

In response to the demand for a more specific imaging agent, there has
been a focus on synthesizing B12-based probes incorporating monocarboxylic acid
derivatives of B12 (MCAs). Mild acid hydrolysis of B12 produces a mixture of
MCAs derived from the b, d, and e propionamide side chains; these side chains
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are more susceptible to the hydrolysis than the a, c, and g side chains.1 While the
MCAs retain vitamin function and normal interaction with HC, modification
certain propionamide side chains affects B12’s ability to bind with TCII,
decreasing relative affinity by less than a factor of 10 for conjugates of the bisomer of the MCA.1,2 By disrupting the binding of B12 to its transfer protein TCII
and inhibiting uptake by TCII receptors, building B12–based conjugates
incorporating MCAs are ideal to prevent non-targeted organ uptake and target the
cancer cells that express HC de novo with a high signal-to-noise ratio.1

6.2 Synthesis of MCAs
Marques and Scooby investigated the optimal reaction conditions for the
generation of MCAs, reporting that maximum conversion (42% yield) of B12 to
the e, b, and d MCA isomers occurred in 1 M hydrochloric acid (HCl) at 50°C for
2 hours.36

B12 (cyanocobalamin, 50 mg, 36.9 mmol) was dissolved in 5mL of 1 M
HCl and allowed to react for 2 h at 50°C (Figure 6.1). The reaction was
neutralized with 1 M sodium hydroxide (NaOH) and loaded on Amberlite ion
exchange resins for desalting. The reaction was eluted from the resins in 100%
MeOH, dried in vacuo, and redissolved in 10 mL H2O.
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Figure 6.1. The conversion of B12 to B12 MCA via acid hydrolysis (the b-acid
isomer is shown).

6.3 Purification of MCAs
The crude reaction was purified by fast protein liquid chromatography
(FPLC) using a 5 mL diethylaminoethyl (DEAE) Sepharose Hi Trapanionexchange column chromatographyon an AKTA prime plus liquid instrument with
an automated fraction collector and UV detection at 280 nm (GE Healthcare). All
runs were carried out at 4°C. The reaction was filtered through a 0.64µm filter
and loaded at 0.5 mL/min in 100% H2O. After the initial flow-through peak
(confirmed by MALDI-TOF/MS to be unreacted B12), the MCAs were eluted at
2.5 mL/min at 2% 1 M NaCl and collected as a single fraction for subsequent
purification by HPLC. B12-dicarboxylic and tricarboxlic acids (confirmed by
MALDI-TOF/MS) were eluted together at 100% 1 M NaCl (Figure 6.2).

58

Figure 6.2. FPLC trace of crude B12 MCA reaction. The MCAs elute at 2% 1
M NaCl in the second peak at 36 min.

The peak that eluted at 2% 1 M NaCl (36 min) was dried in vacuo and
redissolved in 5 mL H2O for a second purification by reversed-phase highperformance liquid chromatography (RP-HPLC) using an Semiprep Eclipse
XDB-C18 column (9.4 mm X 250 mm, 5 µm particle size) (Agilent Technologies,
Santa Clara, CA) on an Agilent 1200 series instrument with a quaternary pump
and UV detection at 360 nm. This purification was optimized to separate the
MCA isomers.

The solvents that were used for elution included (A) 50 mM phosphate
buffer pH 6.5 and (B) MeCN. At a flow rate of 3.0 mL/min, the gradient was (1)
5–15% B over 0–15 min, (2) 15% B for 15-20 min, (3) 15–50% B over 20-26
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min, and (4) 50–5% B over 26–32 min. The trace is shown in Figure 6.3. Three
prominent peaks at Tr=14.89 min, 15.87 min, and 17.12 min were collected, dried
in vacuo, and loaded on Amberlite ion exchange resins for desalting. Each peak
was eluted from the resins in 100% MeOH, dried in vacuo, and characterized by
MALDI-ToF/MS and 2D Heteronuclear Single Quantum Coherence NMR (2D
NMR HSQC).

6.4 Characterization of MCAs
The purity of the MCAs were confirmed by MALDI-ToF/MS, with significant
peaks seen at 1330.6 m/z [M+ - CN] and 991.4 [M+ -CN-base-sugar-PO4].
Unreacted B12 from the reaction gave related yet distinctly different peaks at
1329.6 m/z [M+ - CN] and 990.5 [M+ -CN-base-sugar-PO4].
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Figure 6.3. MALDI-ToF/MS spectrum of peak 3 from RP-HPLC.

Isomer assignments, based on 2D NMR HSQC taken in deuterium oxide
(D2O), were: Peak 1 (Tr=14.89 min) as B12 e-MCA, Peak 2 (Tr= 15.87 min) as B12
d-MCA, and Peak 3 (Tr= 17.12 min) as B12 b-MCA. These assignments are
consistent with literature.36 The yields (by mass) of each isomer are reported in
Table 6.1.

MCA Isomer
e-acid
d-acid
b-acid

RT-HPLC Retention
Time (Tr) in min
14.89
15.87
17.12

Table 6.1. Yield of RT-HPLC Purified MCA Isomers.

Yield
13.9%
12.5%
15.1%

m/z
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6.5 Future Work: Construction of B12 MCA Probes
Because the MCAs bind only to HC, it is hypothesized that MCA-based
probes will demonstrate improved in vivo selectivity and lower systemic toxicity.
The in vivo probes B12enDOTA and B12enNOTA described in Chapter 5 will be
reconstructed using the b-MCA isomer, tested in regards to binding affinity for
TCI and TCII, and evaluated on animal models to compare background uptake in
the kidneys and liver with the unmodified B12 conjugates. In addition, conjugation
through this b-amide position could be used to generate a fluorescent B12-MCA
probe for use as a negative control in in vitro cell testing of B12-based fluorescent
probes, such as those described in Chapter 4.
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7

Optimization of the B12 based fluorescent probe for in vitro cell
screens via incorporation of lanthanide metals

7.1 Challenges of autofluorescence
While the B12-ReThiazole probe described in Chapter 4 was used to
successfully demonstrate the presence of the cubilin receptor in a lung cancer cell
line, the probe was limited by its weak fluorescent signal. In general, light
scattering, reflection, and autofluorescence are all problems associated with
normal fluorescence microscopy, which can decrease the sensitivity and contrast
of the probe signal.37 In particular, the emission of the fluorescent B12ReThiazole was difficult to distinguish from background fluorescence of
molecules naturally present in the cell.38 This natural fluorescence that is seen in
living tissue cultures is due to substances like flavins and porphyrins, which are
all aromatic compounds that also are excitable in the by wavelengths used to
excited the fluorophore region.38

A solution to this problems associated with fluorescent probes is to use
phosphorescent molecules that exhibit delayed luminescence, allowing for the
temporal separation of signals.39 Figure 7.1 depicts a simple Jablonski diagram,
which can be used to illustrate the difference between fluorescence (2) and
phosphorescence (3) in terms of the electronic and vibrational states of a
molecule; the processes differ in the way that electrons behave when excited by a
photon. In both cases, when a molecule is excited with a photon, electrons move
from the lowest energy conformation, the ground state, to a state of higher energy,
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and then relax to the ground state via the emission of a photon. In fluorescence,
the electron is excited to the lowest singlet excited state, and it relaxes to the
ground state without undergoing any spin changes with a decay time of
milliseconds.40 By contrast, the electron in a phosphorescent system undergoes a
spin flip that is “forbidden” by the quantum mechanical rules of electron
transition; it is excited to the lowest triplet state and shows a much longer decay
time on the order of seconds, or longer. As such, time-resolved spectroscopy can
be adjusted to detect only the long-lived emission from the phosphorescent
fluorophore.41

Figure 7.1. Jablonski diagram showing the difference between fluorescent
emission (2) and phosphorescent emission (3). In the simplest case of
fluorescence, the excitation wavelength is defined by photon 1, the electron is
excited to the lowest singlet excited state, and the emission wavelength is
defined by photon 2. In phosphorescence, the emission photon is photon 4.42
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7.2 Lanthanides
The lanthanides (Ln) are the 15 elements from lanthanum to lutetium,
located in the f series of the periodic table (Figure 7.2). Existing essentially in
their trivalent state, Ln+3, and bearing a [Xe]4fn electronic configuration, these
‘hard’ metal ions possess high charge densities and form electrostatic bonds. Ln
ions display large and variable coordination numbers (CN = 6-12), with 8 and 9
often being the most common.43 As ‘hard’ acids, the Ln ions show preferential
binding to ‘hard bases’ such as oxygen, nitrogen or fluorine based ligands, rather
than ‘soft’ bases such as phosphorous, sulphur, or iodine.43
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Figure 7.2. The lanthanides are found in the f series of the period table.
Characterized by the gradual filling of their 4f orbitals, which are well
shielded by the outer core 5s and 5p subshells, these “rare earth elements”
display similar chemical resemblance but have very different physical
properties.43 Figure redrawn in: McMahon, B. Thesis. Trinity College Dublin.
Dublin, Ireland. July 2011.
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7.2.1

Lanthanides as Fluorophores

Scientists have looked towards the lanthanide metals as flurophores for
biomedical analysis, medical diagnosis, and cell imaging.44 The lanthanides
exhibit long lived excited states (microseconds for YbIII and NdIII to
milliseconds for EuIII and TbIII), and the delayed Ln luminescence can be clearly
distinguished from the much shorter lived (sub-microseconds) background
fluorescence, giving an improved signal-to-noise ratio for live-tissue work.45
Figure 7.3 represents the time gating procedure for the detection of lanthanide
luminescence, where excitation occurs via a pulsed lamp or laser, and
measurements are taken after a programmed time delay, allowing the background
luminescence to fade.46 Luminescent Ln ions such as terbium (TbIII), europium
(EuIII), samarium (SmIII), which have emissions in the visible region, and
neodymium (NdIII), ytterbium (YbIII), holmium (HoIII), which have emission in
the NIR region, have been used as diagnostic tools in biomedical analysis, shift
reagents for NMR spectroscopy and as luminescent labels for
fluoroimmunoassays.43 GdIII, EuIII and TbIII are reported as the most emissive.
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Figure 7.3. A graphical representation of the time-gating procedure
displaying the long lived emission of the Ln ions (redrawn in: McMahon, B.
Thesis. Trinity College Dublin. Dublin, Ireland. July 2011).

7.2.2

Indirect Excitation of Lanthanides via the Antennae Effect

In order to maximize the capability of Ln luminescence for fluorescence
studies, their drawbacks must be recognized, and coordinating ligands designed to
help overcome these obstacles.44 A major problem in using these metal ions is the
Laporte-forbidden nature of their f-f transitions, resulting in weak absorptions,
with extinction coefficients of less than 4 M-1cm-1.47 As a result, unless a laser
excitation source or a high ion concentration is used, both of which present
challenges for cell work, direct excitation of these ions rarely yields detectable
luminescence.47 One method used to overcome this problem is the indirect
excitation of the Ln ion via the “antennae effect.”48

The process by which the photophysical emission from the Ln metal is
produced using a simple aromatic system like a phenyl or aromatic chromophore
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is summarized in Figure 7.4, which shows a second Jablonski diagram including
both the sensitizing antenna (Ar) as well as the lanthanide ion (Ln). The ground
state sensitizing antenna (Ar) is excited to its singlet excited state (1Ar) when
absorption of a photon of light of a suitable wavelength occurs. This energy can
be transferred into the antennas triplet state (3Ar) via a spin forbidden intersystem
crossing that is made possible due to the presence of the heavy Ln ion and
significant amounts of spin-orbit coupling occurs. Provided that the energy of the
triplet state lies at least 1700 cm-1 above the accepting Ln energy level,
subsequent population of the Ln excited state (*Ln) will occur via an
intramolecular energy transfer (ET) process. This energy level requirement
prevents any unwanted thermally activated back-energy transfer to the 3Ar state
which would occur if the energy gap was too small.49 However, a compromise
must be met, as if the energy distance between both levels is too large, successful
population of the *Ln state would be hindered.47
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Figure 7.4. The sensitization of lanthanides via the antennae effect.50 Figure
redrawn in: McMahon, B. Thesis. Trinity College Dublin. Dublin, Ireland.
July 2011.

To date, lanthanide complexes have been successfully synthesized and
their usefulness in a variety of cellular studies has been demonstrated.50 These
complexes have been used as pH probes, anion or cation sensors, as well as for
the imaging of biological materials. For example, McMahon et al. explored the
use of a supramolecular Eu(III) complex as a bioprobe for selective imaging of
microcracks in bones often caused by constant stress due to medical conditions
like osteoporosis. The presented cyclen-based bioprobe was found to selectively
bind to bone in exposed calcium(II) sites.51 A cyclen-based Tb (III) bioprobe was
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developed by Bornhop et al. to detect early-stage oral cancer lesions using a
hamster model in vivo.52 The incorporation of Eu(III) and Tb(III) in engineered
cyclen framework holds extraordinary potential for the development of targetspecific bioprobes that can be followed by their characteristic emissions.

7.3 Synthesis of cyclen-based lanthanide complexes for conjugation with B12
It was hypothesized that replacing the rhenium metal with a lanthanide
metal along with a suitable sensitizing chromophore would result in a more
optimized B12-based fluorescent system. In order to design and synthesize a Ln
metal complex that maximized fluorescence and was suitable for B12 conjugation,
a collaboration with Professor Thorfinnur Gunnlaugson lab group at Trinity
College, Dublin was established. The synthesis of the final compound was
carried out in a series of reactions, beginning with the synthesis of the
chromophore and pendant arms, followed by the incorporation of the
chromophore and special pendant arm into a cyclen molecule; the resulting
macrocyclic compound was labeled with europium (EuIII) and terbium (TbIII) to
give the target fluorescent system. Each reaction product was named with initials
and a number.

7.3.1

Cyclen Framework

Other non-radiative and radiative pathways are in constant competition
with the successful population of the *Ln excited state.38 Examples of such
processes include the radiative deactivation of the 1Ar singlet excited state to the
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Ar ground state resulting in molecular fluorescence production, non-radiative
decay of the 1Ar singlet excited state through collisions and vibrational
interactions with surrounding molecules, or the non-radiative decay of the *Ln
excited state through vibrational interactions with other molecules.49 These deactivation processes can be minimized through the use of a rigid metal-ion
environment, free of high-energy vibrations, that also protects the Ln ion from
collisions with the solution molecules.44 Thus, the most successful lanthanide
complexes are based upon the cyclen framework, which forms kinetically inert
and thermodynamically stable metal complexes (Figure 7.5).44 Besides offering a
high degree of stability, these ligands also fulfill the Ln high coordination number
requirement, by providing potentially eight coordinating sites, four by the
macrocyclicnitrogens and four by the flexible pendant arms.

Figure 7.5. The cyclen molecule. As a ligand, cyclen provides a site to attach
a variety of functional groups or ligands, allowing for the functionalization of
the macrocyclic ring and the creation of a phosphorescent system suitable for
a distinct biological role.44
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7.3.2

1-aminoanthroquinone Chromophore

1-aminoanthroquinone was selected as the sensitizing chromophore. EuIII
and TbIII, the two most rigorously studied emissive Ln metal ions, have excited
states that lie at 17200 and 20500 cm-1, respectively. Therefore, the chromophore
needed to have an excited state 1700cm-1 above these values.47 In addition, the
molecule had an absorbance maximum at 360 nm, a wavelength compatible with
the confocal microscope available. The structure of 1-aminoanthroquinone and
the functionalization of the molecule via reaction with chloroacetyl chloride for
future incorporation into the cyclen molecule are shown in Figure 7.6.

Figure 7.6. Synthesis of 1-aminoanthroquinone chromophore.1aminoanthroquinone (1 g, 4.48 mmol, 1 equiv) was dissolved in 100 mL of
DCM with triethylamine (0.49 g/0.69 mL, 4.93 mmol, 1.1equiv). The solution
was cooled in a liquid nitrogen/ethanol bath. Chloroacetyl chloride (0.76g/
0.54 mL, 6.72 mmol, 1.5 equiv) was added drop-wise to the solution over one
hour. Reaction was left stirring overnight.

7.4 Preliminary Data
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For cataloging purposes, the products of each reaction were named with
the prefix ARK and a number that related the order in which they were
synthesized. A peptide arm that offered both an ethyl ester-protected carboxylic
acid for future coupling with B12-ethylenediamine and a reactive chlorine for
reaction with the nitrogen of the cyclen molecule was constructed by reacting
glycine ethyl ester with chloroacetyl chloride; this arm was labeled ARK4. The
functionalized 1-aminoanthroquinone chromophore was labeled ARK11. The
cyclen-based complexes were synthesized in a series of reactions, beginning with
a monoalkylation of the cyclen framework with the chromophore ARK11,
followed by full alkylation with the peptide arm ARK4. An overview synthetic
scheme for the unlabeled lanthanide complex, ARK15, is shown in Figure 7.7.
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Figure 7.7. Synthesis of cyclen-based complex incorporating a 1aminoanthroquinone chromophore and amino acid-based pendant arms
(bottom left).
The compound ARK15 was labeled with europium and terbium to give
the two distinct lanthanide complexes (Figure 7.8). The Ln metals were expected
to be coordinated by the four nitrogen atoms of the cyclen molecule and the four
oxygen atoms on each of the four arms.
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Figure 7.8. ARK15 (0.060 g, 0.070 mmol, 1 equiv) was dissolved in 14 mL of
MeOH with 1:1 molar equivalent of europium triflate (ARK17) or terbium
triflate (ARK21). The reaction was run in the microwave for 40 min at 70 °C.

After acid hydrolysis of the ethyl ester, the final lanthanide complexes
were characterized by 1H NMR, mass spectroscopy, and infrared spectroscopy. In
addition, the complexes were characterized in terms of absorbance, extinction
coefficients, phosphorescent emission, fluorescent emission, excitation spectra,
and the lifetime. Based on the 1H NMR, the final lanthanide complexes were not
pure. While photophysical experiments showed characteristic emission bands for
europium and terbium, the lifetime measurements suggested that the final product
contained at least two distinct species with distinct quantum lifetimes.

7.5 Future work for cyclen-based lanthanide complexes
The lanthanide complexes must be purified and re-characterized by
analytical and photophysical measurements. Once pure, the fully characterized
lanthanide complexes will be conjugated to B12-ethylenediamine via peptide
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coupling to give an optimized fluorescent probe for in vitro confocal microscopy
studies. In addition, these compounds can also be modified so that they may be
used in vivo.

7.5.1

Conjugation with B12

In order to advance the project, the purification must be optimized in order
to yield pure samples of both the EuIII and TbIII compounds. Once isolated, each
species can be characterized by 1H NMR and MALDI-ToF/MS. Purified
lanthanide complexes can then be conjugated with B12-ethylenediamine, and then
entire B12-based lanthanide probe can be purified, characterized, and used in place
of the rhenium probe as a means to screen cell lines for important B12 receptors.

7.5.2

Near-infrared (NIR)-emitting Lanthanides

The antennae moiety on the lanthanide complex can be exchanged to alter
the emission profile of TbIII and EuIII, shifting visible emissions into the nearinfrared region (NIR). Because NIR radiation can penetrate deep into sample
matrices with low light scattering, NIR fluorescent materials show great potential
for in vivo imaging of biological samples with a low background signal.44 The
system would be used in an in vivo, FRET-based detection system that would not
require the use of X-rays or other potentially harmful forms of electromagnetic
radiation.
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8

Implications

One important route to new cellular probes and medical diagnostics with
low toxicity that target rapidly dividing cancer cells is by exploiting these cells’
voracious demand for nutrients. Using vitamin-based pathways for new
diagnostics requires a biochemical and physiological understand ing of the
vitamin and the cancer. With this framework in mind, this project has developed
and assayed a series of B12-based imaging agents for both in vitro and in vivo
applications. A water soluble B12-Re(I) probe that incorporated the thiazolate
linker-chelator moiety was used to demonstrate the presence of cubilin in A549
lung cancer cells. A B12-64Cu probe was also developed and shown to selectively
target tumor cells through TCII receptors in a mouse model.

My findings show that B12-based bioprobes have great promise for
penetrating certain cancer cell lines in vitro—opening up certain pathways for
study for the first time. These remarkable B12 bioprobes developed here also target
tumors selectively as imaging agents for use in vivo. Together, these discoveries
confirm the versatility and strong potential of B12 bioprobes for highlighting
cancers, including the often-elusive metastatic cancers that are so problematic in
the clinic.

Future research will focused on refining the models presented as opposed
to developing other probe constructs with varying ligands. The in vitro B12-based
probe can be modified to improve the signal-to-noise ratio in confocal microscopy
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for in vitro assays by incorporating a lanthanide metal optimized for
phosphorescence in place of the weakly fluorescent rhenium complex. The 64Cu
radiolabeled probe can be improved in terms of its targeting availability by using
B12 derivatives that exclusively bind to HC. As opposed to the widely expressed
TCII receptors in other tissues, HC provides a better target because there is no
membrane-bound HC on noncancerous tissues.

On a cellular level, these compounds can be applied to research questions
in regards to the binding of B12 to its transport proteins and receptors, the
localization and fate of B12 internalized in the cell, and the molecular features that
distinguish cancer cells from normal cells. The in vivo use of these probes allows
for a greater understanding of B12 on the level of the organism, opening up deeper
questions into the differential expression of B12 uptake receptors in varied tissue
types, as well as the mechanisms of B12 storage, clearance, and recycling in the
body. Overall, the work presented in this capstone addresses the needs of the
research and medical communities for probes, which have a future as tools to
better understand the specific biochemistry of B12, the physiology of cancer, and
how these two fields of study overlap to produce an interdisciplinary solution to a
critical health problem.

The broad implications of these findings are further underscored by our
ability to chemically modify the B12 molecule, the ligand, and the metal, which
lends us a great deal of flexibility for future development. Hence thesee probes
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can be adapted for specific experiments and research questions across an
exceptionally broad span of fields, including gastroenterology, oncology, cell
biology, microbiology, and organometallic chemistry. Probes that can detect
cancer far earlier and more reliably are of tremendous significance for improving
outcomes of this most challenging and devastating group of diseases.
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Summary of Capstone Project
The National Cancer Institute (NCI) estimated that ~ 1.5 million
Americans were diagnosed with cancer in 2012 and more than 0.5 million died,
making cancer the second leading cause of death in the US.1 Based on rates from
2007-2009, 41.24% of men and women born today will be diagnosed with a form
of cancer at some point during their lifetime.2

However, trends in epidemiology reflect advances in the field that have
allowed physicians to diagnose and treat cancer more effectively; the five-year
relative survival rate for all cancers diagnosed between 1999 and 2005 increased
50% from the same rate in 1975-1977.1 The NCI emphasizes that finding cancer
at its most treatable stage gives patients the greatest chance of recovery.1
Currently, tumors are most detected blood-work, X-rays, computed tomography
scans, magnetic resonance imaging scans, and positron emission tomography
scans.3 Novel imaging agents that target primary and metastasized tumors offer
hope for improved prognoses in the future, and there is still a great need for
enhanced methods of detection, early or otherwise.

My research has been aimed at synthesizing imaging agents that
selectively target tumor cells through specific receptors for vitamin B12 (B12). B12
1

American Cancer Society. Cancer Facts and Figures 2012; American Cancer Society: Atlanta,
Georgia, 2012; pp 1–64.
2
Howlader N.; Noone, A.M.; Krapcho, M., Neyman, N., Aminou, R., Altekruse, S.F., Kosary,
C.L.; Ruhl, J.; Tatalovich, Z.; Cho, H.; Mariotto, A; Eisner, M.P.; Lewis, D.R.; Chen, H.S.; Feuer,
E.J.; Cronin K.A. SEER Cancer Statistics Review, 1975-2009. National Cancer Institute.
http://seer.cancer.gov/csr/1975_2009 (accessed on March 16, 2013).
3
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is essential for cellular metabolism, growth, and division, and all living cells
require B12 for survival.4 B12 based probes, which exploit the supply route of B12
in order to target regions of extreme cell growth, are also ideal due to the low
toxicity and high water solubility of the vitamin.4

Mammalian cells are unable to synthesize B12, and it must be obtained
through diet. The human body has developed a complex dietary uptake system
based on soluble transport proteins in the mouth, stomach, intestine, and
circulatory system.5 The two main proteins of interest as it pertains to this
research are haptocorrin (HC), which binds to B12 and B12 analogues in the
mouth, stomach and blood serum, and transcobalamin II (TCII), the circulatory
transport protein that facilitates B12 cellular entry and blood-brain barrier
passage.6

The hypothesis of this research is that the B12 pathway can be exploited to
offer a tropism for cancer cells; certain cell lines over-express uptake receptors for
TCII (CD320 receptors) in order to meet the increased B12 demands of rapid and
uncontrolled growth. In addition, it was recently discovered that some cell lines,
like those of pancreatic cancer, express membrane-bound HC de novo.1 This HC

4
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finding has great potential for a more specific targeting of cancer cells. I have
worked to synthesize, characterize and assay a series of B12-based imaging agents
for both in vitro and in vivo applications: a fluorescent B12-based probe with
which to screen cell lines for receptor targets, and also a radiolabelled B12-based
system to translate this work to living organisms.

For in vitro cancer cell screens to study uptake and localization of B12
conjugates, I helped to build, purify, and characterize an optimized B12-based
rhenium I (Re(I)) probe. A fluorescent B12-based probe is useful because it allows
for preliminary screening of living cells to confirm the presence of certain
receptors that are important in the B12 uptake pathway, such as cubilin. For lab
groups that are studying the differential expression of these receptors in varied
tissues, such a construct provides a confirmation of the receptor functionality that
cannot be obtained from genetic methods such as RT-PCR or western Blot. I
synthesized, purified, and characterize a B12-thiazole-Re(I) (1), which
incorporated a bifunctional thiazole ligand that chelates the Re(I) and links to the
B12 molecule. We showed that 1, bound to the intestinal transport protein for B12
termed intrinsic factor, was internalized by lung cancer cells, which reveals its
great potential as a method of screening living cell lines for the cubilin receptor
and suggests the possibility of targeting drugs to lung cancer cells by aerosolizing
B12-drug conjugates. These results were published in Chemical Communications,
2011, 47, 9792-9794, in a paper titled “A water soluble vitamin B12-Re(I)
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fluorescent conjugate for cell uptake screens: use in the conformation of cubilin in
the lung cancer line A549.”7

However, 1 and other B12Re(I) probes were limited by complications of
working with Re(I). We subsequently hypothesized that replacing the rhenium
metal with a lanthanide metal along with a suitable sensitizing chromophore
would result in a more optimized fluorescent system. As in vitro imaging agents,
the lanthanides (LnIII) offer long wavelength emissions and relatively long-lived
excited states (milliseconds).8 The delayed fluorescence allows the LnIII signal to
be distinguished from background autofluorescence. Therefore, my second goal
was to design a LnIII metal complex that maximized fluorescence and was
suitable for B12 conjugation. To accomplish this, I traveled to Ireland to work at
Trinity College, Dublin, in Professor Thorfinnur Gunnlaugsson’s research group.
Over the eight weeks, I designed, synthesized, and photophysically characterized
a series of lanthanide complexes suitable for future B12 conjugation. The
purification and characterization of these compounds remains as future work for
the project.

For the in vivo imaging of tumors, and in response to the promise for copper
radionuclides covalently attached to biological molecules for diagnostic imaging
7
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and targeted radiotherapy, I constructed a B12-based probe by conjugating B12
with a linker molecule, ethylenediamine (en), and a metal-chelating macrocyclic
ligand, 1,4,7,10-tetraazacyclododecane-N’,N’’,N’’’,N’’’’-tetraacetic acid
(DOTA). The resulting compound, B12enDOTA (2), offers a site for facile
radiolabeling. 2 was purified by a two-step purification method involving an
analytical anion exchange column and a C18 analytical column on reverse phase
HPLC (RP-HPLC). The purity of 2 was confirmed by nuclear magnetic
resonance spectrometry (1H NMR) and matrix-assisted laser
desorption/ionization-time of flight mass spectrometry (MALDI-TOF/ MS). In
collaboration with the Washington University Medical School in St. Louis,
Missouri, 2 was labeled with copper-64 (64Cu) , a radioactive derivative of copper
for use in positron emission topography (PET) scanning. Initial 64Cu-labeling
experiments were successful, showing 100% radiolabeling, the labeled analogue
of 2 was tested in vivo in a mouse model, showing 2% tumor distribution in two
different tumor models. A more stable chelator molecule, 1,4,7triazacyclononane-N,N′,N′′-triacetic acid (NOTA), was selected for a revised
probe construct. The optimized compound B12enNOTA (3) is expected to show a
higher expected degree of kinetic stability in regards to chelating the 64Cu
compared to 2. In vivo experiments with 3 are currently underway at Washington
University.

While B12-based imaging agents have experimentally labeled tumor tissue
through successful receptor-mediated endocytosis of the TCII-bound B12
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conjugate, significant background levels of radioactivity were detected in normal
tissues.9 In particular, high uptake is seen in the kidneys and the liver because
these organs are responsible for clearing and storing B12, respectively. High
uptake of radiolabeled compounds in the kidney may lead to radiation toxicity,
and the radiation dose to the kidney is often the “dose-limiting” factor for the
clinical use of nuclear medicine, and the highest expression of CD320 is seen in
the kidneys, which poses a problem for the development of B12-based
therapeutics.9 A solution to this problem would be to knock out the B12
conjugate’s ability to bind with TCII, yet maintain binding with other important
transport proteins. Additionally, Waibel et al. suggest that a B12-based probe with
decreased binding with TCII would clear from the blood more quickly than the
transport protein-bound form, decreasing overall systemic toxicity.9

In response to the demand for a more specific imaging agent, there has
been a focus on synthesizing B12-based probes incorporating monocarboxylic acid
derivatives of B12 (MCAs). It is known that mild acid hydrolysis of B12 produces
a mixture of MCAs derived from the b-, d-, and e- propionamide side chains.
While the MCAs retain vitamin function and normal interaction with HC,
modification certain propionamide side chains affects B12’s ability to bind with
TCII, decreasing relative affinity by less than a factor of 10 for conjugates of the

9
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b-isomer of the MCA.10 By disrupting the binding of B12 to its transfer protein
TCII and inhibiting uptake by TCII receptors, B12–based conjugates incorporating
MCAs are ideal to prevent non-targeted organ uptake and target the cancer cells
that express HC de novo with a high signal-to-noise ratio.10

I have synthesized, purified, and characterized the B12-monocarboxylic
acids. Cyanocobalamin was reacted with 5.0M hydrochloric acid for two hours
under heat (50 °C). The reaction was neutralized with 5.0M sodium hydroxide
and desalted using Amberlite ion exchange resins. Purification was a two-step
process, involving a cation exchange column followed by a C18 analytical column
(HPLC). The b-, c-, and e- acids were characterized using MALDI-ToF/MS and
13

C NMR.

The next step is to synthesize comparable compounds of 1, 2, and 3
utilizing the b-monocarboxylic acid derivative of B12. Conjugation through the bamide position could be used to generate a fluorescent B12-MCA probe for use as
a negative control in in vitro cell testing of B12-based fluorescent probes. Because
the MCAs bind only to HC, it is hypothesized that MCA-based probes will
demonstrate improved in vivo selectivity and lower systemic toxicity. The in vivo
probes B12enDOTA and B12enNOTA will be reconstructed using the b-MCA
isomer, tested in regards to binding affinity for TCI and TCII, and evaluated on
10
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animal models to compare background uptake in the kidneys and liver with the
unmodified B12 conjugates. With such derivatives, it is expected that visualization
in the PaCa-2 cells would be shut down while being increased in the B16 cells.

In conclusion, a series of B12-based imaging agents were synthesized,
characterized, and assayed for both in vivo and in vitro functions. A water soluble
B12-Re(I) probe that incorporated the thiazolate linker-chelator moiety was used
to demonstrate the presence of cubilin in A549 lung cancer cells, and a B12-64Cu
probe was shown to selectively target tumor cells through specific receptors for
B12 in a rat model. These findings suggest that vitamin B12-based bioprobes have
great promise for studying the B12 uptake pathway in certain cancer cell lines in
vitro and targeting tumors as imaging agents in vivo.
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